The Role of Fibrate Treatment in Dyslipidemia: An Overview

Author(s): Niki Katsiki, Dragana Nikolic, Giuseppe Montalto, Maciej Banach, Dimitri P. Mikhailidis, Manfredi Rizzo.

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 17 , 2013

Become EABM
Become Reviewer

Abstract:

Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias.

Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributing to dyslipidemia management, particularly in patients with diabetes (DM) or the metabolic syndrome (MetS). Furthermore, fibrates exert beneficial effects on adipokines, inflammation and oxidative stress as well as neuroprotective properties. However, further studies are needed to define the role of fibrates in the prevention of CV events. We review the effects of fibrates on atherogenic dyslipidemia and CV risk reduction.

Keywords: Fibrates, dyslipidemia, cardiovascular risk, diabetes.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 17
Year: 2013
Page: [3124 - 3131]
Pages: 8
DOI: 10.2174/1381612811319170020

Article Metrics

PDF: 59